Author, as appears in the article.: Utrillo L, Vidal F, Puig T, Domingo P

Department: Medicina i Cirurgia

URV's Author/s: Vidal Marsal, Francisco

Keywords: Virologically suppressed adults Toxicity Tenofovir disoproxil fumarate Switching Safety Reverse-transcriptase inhibitor Randomized comparative trial Pi Open-label Once-daily dolutegravir Nrti Nnrti Insti Infected patients Hiv-1-infected patients Combination antiretroviral therapy Boosted protease inhibitor Bone-mineral density switching safety pi nrti nnrti insti combination antiretroviral therapy

Abstract: Introduction: There are multiple reasons to switch from a virologically successful antiretroviral regimen. Some of them are related to toxicity. Lately, combination antiretroviral treatment (cART) switches have often been related to drug-drug interactions which may also eventually entail safety issues as well. Areas covered: The purpose of this review is to analyze causes of switching between virologically successful cART regimes related to safety issues. The most relevant papers were selected and summarized. Expert opinion: Switching cART has been a popular strategy to address safety issues throughout the antiretroviral era. The myriad of switching studies have paralleled the study and release into clinical practice of new antiretroviral drugs with different and often improved safety profiles. Most of them have been successful in improving antiretroviral toxicity while keeping HIV replication under control. However, it should be taken into account that, whenever a new drug is given, there is a possibility of new drug-related toxicity. Notwithstanding that, an increase in cART switching is foreseen, given the fact that we have a wide antiretroviral drug armamentarium and that people living with HIV are ageing and thus more prone to developing age-related co-morbidities whose therapies may entail new interactions and eventually new toxicities.

Research group: Grup de Recerca Biomèdica HJ23

Thematic Areas: Saúde coletiva Pharmacology (medical) Pharmacology & pharmacy Medicine (miscellaneous) Medicina iii Medicina ii Medicina i Ciências biológicas i

licence for use: https://creativecommons.org/licenses/by/3.0/es/

Author's mail: francesc.vidal@urv.cat

Author identifier: 0000-0002-6692-6186

Record's date: 2023-04-01

Papper version: info:eu-repo/semantics/acceptedVersion

Link to the original source: https://www.tandfonline.com/doi/full/10.1080/14740338.2016.1206076

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Papper original source: Expert Opinion On Drug Safety. 15 (10): 1349-1360

APA: Utrillo L, Vidal F, Puig T, Domingo P (2016). Switching antiretroviral regimes for the treatment of HIV: safety implications. Expert Opinion On Drug Safety, 15(10), 1349-1360. DOI: 10.1080/14740338.2016.1206076

Article's DOI: 10.1080/14740338.2016.1206076

Entity: Universitat Rovira i Virgili

Journal publication year: 2016

Publication Type: Journal Publications